BIIB Earnings & Financial Statements
Biogen Inc.
$232.83
+$3.93(+1.72%)
72
Overall
80
Value
91
Tech
47
Quality
Market Cap
$34.40B
Volume
1.95M
52W Range
$138.00 - $230.49
Target Price
$239.19
BIIB earnings and financial statements: Biogen Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
BIIB Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B |
| Cost of revenue | $2.40B | $2.31B | $2.53B | $2.28B | $2.11B |
| Operating income | $3.27B | $2.98B | $2.29B | $3.26B | $4.57B |
| EBITDA | $2.34B | $2.58B | $1.79B | $4.11B | $2.88B |
| Net income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B |
| EPS (diluted) | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B |
| Total liabilities | $11.18B | $11.33B | $12.05B | $11.17B | $12.92B |
| Shareholders’ equity | $18.26B | $16.72B | $14.80B | $13.40B | $10.90B |
| Long-term debt | $6.58B | $4.88B | $7.19B | $6.61B | $6.60B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $2.20B | $2.88B | $1.55B | $1.38B | $3.64B |
| Capital expenditure | -$185.40M | -$271.20M | -$311.40M | -$243.20M | -$294.90M |
| Free cash flow | $2.02B | $2.52B | $1.24B | $1.14B | $3.35B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BIIB | $232.83 | +1.7% | 1.95M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |